Functional Constipation (FC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Functional Constipation (FC) Market Outlook

Thelansis’s “Functional Constipation (FC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Functional Constipation treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Functional Constipation (FC) Overview

Functional constipation (FC) is a condition that is diagnosed according to the Rome IV criteria. It involves the presence of two or more of the following symptoms: straining during at least 25% of defecations, lumpy or hard stools in at least 25% of defecations, the sensation of incomplete evacuation for at least 25% of defecations, the sensation of anorectal obstruction/blockage for at least 25% of defecations, manual manoeuvres to facilitate at least 25% of defecations, and fewer than three spontaneous bowel movements per week. Loose stools are rarely present in functional constipation without using laxatives, and the patient should not meet the criteria for irritable bowel syndrome. Functional constipation (FC) has three subtypes: normal transit constipation, slow transit constipation, and outlet constipation. Normal transit constipation occurs when there is a self-reported perception of constipation despite normal stool movement through the colon. Slow transit constipation occurs when there is prolonged transit time through the colon, as confirmed by a motility study. Outlet constipation (dyssynergic defecation) results from pelvic floor dysfunction when there is a defect in the coordination required for stool evacuation. Treatment for functional constipation depends on the underlying cause. Slow transit constipation can benefit from increased fluid intake, fibre supplementation, magnesium supplementation, and stool softener or laxative use. Non-stimulant laxatives are preferred to stimulant laxatives because the latter can cause dependency and decreased bowel function over time. Pelvic floor PT is recommended for treating dyssynergic defecation.

• In the general population, chronic constipation affects around 15%, across all ages and genders, with estimated figures ranging from 2% to 27%. Females are more prone to experiencing constipation, with a female-to-male ratio of 2.2:1.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: